Evidence map›Paper›PMID 20663926›Full record

ArticleMolecular cancer therapeutics2010

Heat shock protein 90 inhibition depletes TrkA levels and signaling in human acute leukemia cells.

Rekha Rao, Srilatha Nalluri, Warren Fiskus, Ramesh Balusu, Atul Joshi, Uma Mudunuru, Kathleen M Buckley, Kelly Robbins, Celalettin Ustun, Gary W Reuther and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Molecular cancer therapeutics, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Rekha RaoMedical College of Georgia Cancer Center, 1120 15th Street CN 2133, Augusta, GA 30912, USA.
Srilatha Nalluri
Warren Fiskus
Ramesh Balusu
Atul Joshi
Uma Mudunuru
Kathleen M Buckley
Kelly Robbins
Celalettin Ustun
Gary W Reuther
Kapil N Bhalla
Moffitt Cancer Center · US

Funding

Heat shock protein 90 antagonist-based therapy of mantle cell lymphomaR01CA129962 · NCI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI BHALLA, KAPIL · 2008 to 2012
$1.5M
Histone Deacetylase Inhibitors in CMLR01CA116629 · NCI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI BHALLA, KAPIL · 2005 to 2009
$1.4M
Histone Deacetylase Inhibitor Based Therapy of AMLR01CA123207 · NCI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI BHALLA, KAPIL · 2007 to 2011
$1.3M
NCI NIH HHS R01 CA116629NCI NIH HHS R01 CA123207NCI NIH HHS R01 CA129962
6 · The paper itself

Abstract

Nerve growth factor (NGF) induces autophosphorylation and downstream progrowth and prosurvival signaling from the receptor tyrosine kinase TrkA. Overexpression or activating mutation of TrkA has been described in human acute myeloid leukemia cells. In the present study, we show the chaperone association of TrkA with heat shock protein 90 (hsp90) and the inhibitory effect of the hsp90 inhibitor, 17-DMAG, on TrkA levels and signaling in cultured and primary myeloid leukemia cells. Treatment with 17-DMAG disrupted the binding of TrkA with hsp90 and the cochaperone cdc37, resulting in polyubiquitylation, proteasomal degradation, and depletion of TrkA. Exposure to 17-DMAG inhibited NGF-induced p-TrkA, p-AKT, and p-ERK1/2 levels, as well as induced apoptosis of K562, 32D cells with ectopic expression of wild-type TrkA or the constitutively active mutant Delta TrkA, and of primary myeloid leukemia cells. Additionally, 17-DMAG treatment inhibited NGF-induced neurite formation in the rat pheochromocytoma PC-12 cells. Cotreatment with 17-DMAG and K-252a, an inhibitor of TrkA-mediated signaling, induced synergistic loss of viability of cultured and primary myeloid leukemia cells. These findings show that TrkA is an hsp90 client protein, and inhibition of hsp90 depletes TrkA and its progrowth and prosurvival signaling in myeloid leukemia cells. These findings also support further evaluation of the combined activity of an hsp90 inhibitor and TrkA antagonist against myeloid leukemia cells.

Indexed as

Signal TransductionAnimalsBenzoquinonesBone Marrow CellsCarbazolesCell DifferentiationCell Line, TumorCoculture TechniquesHSP90 Heat-Shock ProteinsHumansIndole AlkaloidsLactams, MacrocyclicLeukemia, Myeloid, AcuteNerve Growth FactorPC12 CellsPhosphorylation17-(dimethylaminoethylamino)-17-demethoxygeldanamycinBenzoquinonesCarbazolesHSP90 Heat-Shock ProteinsIndole AlkaloidsLactams, MacrocyclicNerve Growth FactorPolyubiquitinProteasome Endopeptidase ComplexReceptor, trkAstaurosporine aglycone

Identifiers

PMID20663926
PMCPMC3008427
OpenAlexW2125994014

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.